Skip to content
1 min left
0% read
OpenCV.ai logo

OpenCV.ai

Technology Company
Palo Alto, California, USA
Founded 2020
50

The computer vision consulting company of OpenCV.org, the popular CV library. We develop custom software AI solutions.

Share:

Who We Are?

We are a world-class team delivering AI solutions.

OpenCV.ai is the professional consulting arm of OpenCV.org - the world's largest open-source computer vision library that powers CV pipelines worldwide.

What Do We Do?

  • We create practical AI solutions for startups and large enterprise companies.
  • Training & developing cutting-edge neural networks
  • Optimizing models for edge computing
  • Creating custom hardware

Why Choose Us?

More than 50 successful projects including 6 companies from the Fortune 100 list.

Frequently Asked Questions About OpenCV.ai

OpenCV.ai is a finance company. The computer vision consulting company of OpenCV.org, the popular CV library. We develop custom software AI solutions.

Who we are? We are a world-class team delivering AI solutions OpenCV.ai is the professional consulting arm of OpenCV.

org - the world's largest open-source Computer Vision library that powers CV pipelines worldwide. What do we do? We create practical AI solutions for startups and large enterprise c.

OpenCV.ai has been operating since 2020. You can verify their legitimacy through their official website and social media presence.

OpenCV.ai operates in the finance sector of the cryptocurrency industry. Compare OpenCV.

ai with other finance companies on Crypto News Navigator to evaluate services, features, and reputation before making your decision.

Before using OpenCV.ai, research their track record (operating since 2020), verify their regulatory compliance, read user reviews, and understand their fee structure. Never share your private keys with any service, and start with small amounts until you are comfortable with the platform.

Safety depends on multiple factors including regulatory compliance, security practices, and track record. OpenCV.ai is based in Palo Alto, California, USA, has been operating since 2020.

Always enable two-factor authentication, use strong passwords, and never store large amounts on any third-party platform.

OpenCV.ai is based in Palo Alto, California, USA, North America.

OpenCV.ai was founded in 2020. The company currently has 50 employees.

OpenCV.ai Details

OpenCV.ai Tags

More About OpenCV.ai

Work Model Details
Employees work from physical offices.

Latest from Academy

Blast Ecosystem Grew 400% in Six Months and Nobody Talked About It

Blast Ecosystem Grew 400% in Six Months and Nobody Talked About It

The Blast ecosystem has been crypto's most misunderstood narrative of 2026. While the market fixated on a 98.3% drawdown from all-time highs, less-publicized on-chain data tells a counterintuitive story. Three major protocol upgrades shipped since January 2025, 10% TVL growth appeared week-on-week in April, and 279,520 holders remain HODLing their positions on a chain the world has given up on.

7m
 Why Tokenlon's Revenue Doesn't Match Its Token Price

Why Tokenlon's Revenue Doesn't Match Its Token Price

DEX aggregation is "solved" in DeFi, right? 1inch, Jupiter, Paraswap have you covered. Except the data paints a different picture. Tokenlon quietly processes over $120 million in weekly trading volume and a 99.71% order success rate, yet remains shockingly absent from discussion in industry forums and panels. Either the market is correct and Tokenlon's fundamentals are not what we perceive, or a highly-traveled protocol has been willfully ignored.

Mia Halland logoMia HallandApr 26, 2026
8m
Sixty-Five Million in BioDAOs, BIO at One Cent

Sixty-Five Million in BioDAOs, BIO at One Cent

Bio Protocol's CEO recently revealed that PeptAI designed a new ADHD peptide candidate in 24 hours for roughly $1,500 in initial lab validation. While crypto traders focus on memecoins, Bio Protocol has quietly built a scientific funding platform backed by Pfizer Ventures, Binance Labs, and Arthur Hayes' Maelstrom Fund. The bio price trades at $0.031, down 96.5% from its all-time high of $0.889, despite $65M in combined BioDAO research funding and active clinical trials.

8m